Alzheimer's Disease, Cortical Basal Syndrome, Frontotemporal Dementia, Progressive Supranuclear Palsy, Vascular Cognitive Impairment
Conditions
Brief summary
This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV). Subjects will be recruited from the patient population and healthy volunteers of Taiwan residents. This study protocol requires each subject to complete the following components: screening evaluation, brain MRI and 18F-PM-PBB3 PET imaging up to two sessions. The screening procedures will include neuropsychological assessments, vital signs, ECG, physical examinations and laboratory tests. In addition, 18F-AV-45 PET imaging result will be as a part of inclusion criteria to confirm presence of amyloid deposition in patients with clinically diagnosed probable AD or absence of amyloid deposition in FTD, VCI and HV subjects. Furthermore, 18F-AV-133 PET imaging data will also be as a part of inclusion criteria to confirm the diagnosis of PSP and CBS. All subjects will complete clinical assessments and clinical safety tests to ensure the subject is medically stable to complete the study protocol. The screening procedures will occur within 30 days prior to 18F-PMPBB3 PET imaging.
Interventions
DRUGF-18
This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
Sponsors
Chang Gung Memorial Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
1. Written informed consent must be obtained before any assessment is performed. 2. Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to use a barrier contraception method for the duration of the study. 3. Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects for the study duration. 4. Male subjects must not donate sperm for the study duration. 5. Willing and able to cooperate with study procedures
Exclusion criteria
1. Implantation of metal devices including cardiac pacemaker, intravascular metal devices. 2. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes (except for patients with VCI), acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases. 3. Current or prior history of major psychiatric disorders, epilepsy and major depression. 4. History of severe allergic or anaphylactic reactions particularly to the tested drugs. 5. History of positive test for human immunodeficiency virus (HIV). 6. Life expectancy less than 1 year. 7. Pregnant women, lactating or breast-feeding women. 8. Clinically significant abnormal laboratory values and/or clinically significant or unstable medical or psychiatric illness. 9. Substance abuse or alcoholism for at least 3 months. 10. Cognitive impairment resulting from trauma brain injury. 11. Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds the effective dose of 50 mSv. 12. Subject has received an investigational drug or device within 30 days of screening 13. Patients in whom MRI was contraindicated and with history of claustrophobia in MRI 14. General MRI, and / or PET
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome measures are to evaluate the dosimetry of novel radiotracer 18F-PM-PBB3 in human. | YEAR ONE | Time-integrated activity in each organ will be calculated by trapezoidal integration of the first 45 min of the organ's time-activity curve, followed by a single-exponential fit to the remaining data points (based on the 4 whole-body images) extrapolate to infinity, all base on non-decay-corrected data.Residence times will be obtained by dividing the time-integrated activity by the injected amount of activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Optimal scanning time for brain imaging using 18F-PM-PBB3 . | YEAR ONE | PET data will be acquired using SIMENS PET/CT or PET/MRI scanner with an axial field of view of 15.7cm. For PET/CT protocol, a 50-min dynamic brain PET scan (6x10s, 4x60s, 5x180s, 6x300s) will be started simultaneously with the injection of 10mCi of 18F-PM-PBB3 after a low-dose CT scan for patient positioning and attenuation correction. |
Countries
Taiwan
Outcome results
None listed